Taskforce for the Generation of Evidence to Resolve the Gout Care Guideline Conflict (TOGETHER) Conference

生成证据以解决痛风护理指南冲突的工作组(TOGETHER)会议

基本信息

  • 批准号:
    9471664
  • 负责人:
  • 金额:
    $ 2.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-20 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

Gout is the most common form of inflammatory arthritis (affecting 8.3 million US adults). The disease is complicated by a high level of cardiovascular-metabolic-renal comorbidities and their sequelae (e.g., myocardial infarction and premature death). Furthermore, remarkably suboptimal gout care has led to frequent flares, a doubling of hospitalization rates, and an increased economic burden in the US. A key reason behind this suboptimal care has been found to be a lack of knowledge or acceptance about the utility/role of serum uric acid (SUA) among primary care providers (PCPs) and patients alike. While the mainstay of gout rheumatology guidelines has been a treat-to-target SUA level (e.g., SUA <6 mg/dL) approach, SUA is not even measured in the majority of patients in current PCP practice, even after ULT is prescribed. In fact, in 2016, the American College of Physicians (ACP) published its own version of guidelines for gout directly refuting this approach by stating that “There is no evidence from an experimental study that examined the health outcomes of treating to one serum uric acid level versus another, nor is there a trial comparing a strategy of basing treatment on attaining a specific urate level versus basing treatment on reduction in symptoms (such as gout flares).” The obvious implication of the ACP guidelines conflicting with rheumatology guidelines is the worsening of the already suboptimal gout care in the US and beyond. To that end, it is imperative that all stakeholders get together to formulate a plan for where to go from here, particularly with regard to building the evidence necessary to resolve this gout guideline conflict. To initiate this process, we propose to convene a conference (the Taskforce for the Generation of Evidence to Resolve the Gout Care Guideline Conflict [TOGETHER] Conference) including key rheumatology gout investigators, the ACP guideline leadership group, general practitioners, and gout patients (consumers). The aims of the TOGETHER conference are to assemble key investigators and consumer networks to ultimately resolve the gout guideline conflict (Aim 1); to prioritize specific study questions and develop concrete steps to fill the key evidence gaps (Aim 2), and to provide mentorship about evidence generation, guideline development processes, and gout research for young investigators and trainees, with a focus on encouraging the participation and training of females and underrepresented minority groups (Aim 3). It is anticipated that a key outcome of this meeting will be the creation of a network of specialist and GP researchers as well as consumers that will have a productive and collaborative relationship to generate consistent and evidence-based gout care guidelines. The proceedings of this meeting will be disseminated through a web recording and peer-reviewed publication. Consistent with the mission of the NIH/NIAMS, this meeting will successfully specify and prioritize research goals and steps to fill the critical evidence gap, which will ultimately lead to the resolution of the gout guideline conflict, a major additional source of the suboptimal gout care in the US and beyond.
痛风是最常见的炎症性关节炎(影响830万美国成年人)。这种疾病是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HYON K CHOI其他文献

HYON K CHOI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HYON K CHOI', 18)}}的其他基金

The Risk and Risk Factors of Incident Hydroxychloroquine Retinopathy Among Long-Term Users
长期使用者发生羟氯喹视网膜病变的风险和危险因素
  • 批准号:
    9973207
  • 财政年份:
    2019
  • 资助金额:
    $ 2.2万
  • 项目类别:
Methodologic Remedies for the Risk Factor Paradox in Osteoarthritis Progression
骨关节炎进展中危险因素悖论的方法学补救措施
  • 批准号:
    9134044
  • 财政年份:
    2015
  • 资助金额:
    $ 2.2万
  • 项目类别:
Impact of Cardiovascular and Weight Loss diets on Uric Acid and Gout Risk
心血管和减肥饮食对尿酸和痛风风险的影响
  • 批准号:
    8631343
  • 财政年份:
    2013
  • 资助金额:
    $ 2.2万
  • 项目类别:
Impact of Cardiovascular and Weight Loss diets on Uric Acid and Gout Risk
心血管和减肥饮食对尿酸和痛风风险的影响
  • 批准号:
    9039786
  • 财政年份:
    2013
  • 资助金额:
    $ 2.2万
  • 项目类别:
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT
高尿酸血症和痛风的新代谢物和微生物途径
  • 批准号:
    10612960
  • 财政年份:
    2013
  • 资助金额:
    $ 2.2万
  • 项目类别:
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT
高尿酸血症和痛风的新代谢物和微生物途径
  • 批准号:
    10444188
  • 财政年份:
    2013
  • 资助金额:
    $ 2.2万
  • 项目类别:
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares
项目 2:痛风发作的新危险因素和精准医学
  • 批准号:
    10017005
  • 财政年份:
    2012
  • 资助金额:
    $ 2.2万
  • 项目类别:
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares
项目 2:痛风发作的新危险因素和精准医学
  • 批准号:
    10263205
  • 财政年份:
    2012
  • 资助金额:
    $ 2.2万
  • 项目类别:
Clinical and Cost-effectiveness of biologics in Rheumatoid Arthritis
生物制剂治疗类风湿关节炎的临床和成本效益
  • 批准号:
    7833490
  • 财政年份:
    2009
  • 资助金额:
    $ 2.2万
  • 项目类别:
Clinical and Cost-effectiveness of biologics in Rheumatoid Arthritis
生物制剂治疗类风湿关节炎的临床和成本效益
  • 批准号:
    7943898
  • 财政年份:
    2009
  • 资助金额:
    $ 2.2万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 2.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了